Cellular adhesion molecules in urologic malignancies

American Journal of Clinical Pathology

Volumn 107, Issue 1, 1997, Pages 56-63

  Cohen, Michael B ^a   Griebling, Tomas L ^a   Ahaghotu, Chiledum A ^a   Rokhlin, Oskar W ^a   Ross, Jeffrey S ^b  

^a UNIVERSITY OF IOWA   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

CD44; E cadherin; Prostatic neoplasms; Renal cell carcinoma; Transitional cell carcinoma

Indexed keywords

CADHERIN; CELL ADHESION MOLECULE; HERMES ANTIGEN; IMMUNOGLOBULIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; SELECTIN; UVOMORULIN;

BLADDER CANCER; CANCER INVASION; CELL INTERACTION; EXTRACELLULAR MATRIX; HUMAN; KIDNEY CARCINOMA; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TESTIS CANCER; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER;

EID: 0031043079     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/107.1.56     Document Type: Review

References (107)

1. Edelman GM. A golden age for adhesion. Cell Adh Comm. 1993; 1:1-7.
2. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J. 1990;4:2868-2880.
3. Honn KV, Tang DG. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev. 1992;11:353-375.
4. Pigott R, Power C. The Adhesion Molecule Facts Book. New York, NY: Academic Press, 1993.
5. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425-434.
6. Van Kooyk Y, Figdor CG. Activation and inactivation of adhesion molecules. Curr Top Microbiol Immunol. 1990;184:235-248.
7. Shiozaki H, Oka H, Inoue M, Tamura S, Mondem M. E-cadherin mediated adhesion system in cancer cells. Cancer. 1996; 77:1605-1613.
8. Takayama T, Shiozacki H, Shibamoto S, et al. Beta-catenin expression in human cancers. Am J Pathol. 1996;148:39-46.
9. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest. 1993;68:4-17.
10. Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol. 1994;127:1375-1380.
11. Shibamoto S, Hayakawa M, Takeuchi K, et al. Association of p120, a tyrosine kinase substrate with e-cadherin/catenin complexes. J Cell Biol. 1995;128:949-957.
12. Shiozaki H, Iihara K, Oka H, et al. Immunohistochemical detection of alpha-catenin expression in human cancers. Am J Pathol. 1994;144:667-674.
13. Natt E, Magenis RE, Zimmer J, Mansouri A, Scherer G. Regional assignment of the human loci for uvomorulin (UVO) and chymotrypsinogen B (CTRB) with the help of 2 overlapping deletions of the long arm of chromosome 16. Cytogenet Cell Genet. 1989;15:145-148.
14. Oka H, Shiozaki H, Kobayashi K, Inoue M, et al. Expression of e-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53:1696-1701.
15. Nagafuchi A, Shirayoshi Y, Okazaki Y, Yasuda K, Takeichi M. Transformation of cell adhesion properties by exogenously induced e-cadherin cDNA. Nature. 1987;329:341-343.
16. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 1993;142:987-993.
17. Dorudi S, Sheffield JP, Poulsom R, Northover JM, Hart IR. Ecadherin expression in colorectal cancer: an immunocytochemical and in-situ hybridization study. Am J Pathol. 1993; 142:981-986.
18. Pignatelli M, Liu D, Nasim MM, et al. Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells. Br J Cancer. 1992;66:629-634.
19. Mayer B, Johnson JP, Leitl F, et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 1993;53:1690-1695.
20. Shimoyama Y, Nagafuchi A, Fujita S, et al. Cadherin dysfunction in a human cancer cell line: possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiven ess. Cancer Res. 1992;52:5770-5774.
21. Bussemakers MJG, van Moorselaar RJA, Giroldi LA, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res. 1992;52:2916-2922.
22. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992;52:5104-5109.
23. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB. Reduction of E-cadherin levels and deletion of the a-catenin gene in human prostate cancer cells. Cancer Res. 1993; 53:3585-3590.
24. Giroldi LA, Schalken JA. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev. 1993;12:29-37.
25. Otto T, Rembrink K, Goepel M, Meyer-Schwickerath M, Rübben H. E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. Urol Res. 1993;21:359-362.
26. Ross JS, Figge HL, Bui HX, et al. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol. 1994;7:835-841.
27. Rokhlin OW, Cohen MB. Expression of cellular adhesion molecules on human prostate tumor cell lines. Prostate. 1995; 26:205-212.
28. MacCalman CD, Brodt P, Doublet JD, et al. The loss of E-cadherin mRNA transcripts in rat prostatic tumors is accompanied by increased expression of mRNA transcripts encoding fibronectin and its receptor. Clin Exp Metastasis. 1994;12:101-107.
29. Daniel JM, Reynolds AB. The tyrosine kinase substrate p120cas binds directly to E-cadherin but not to the adenomatous polyposis coli protein or alpha-catenin. Mol Cell Biol. 1995; 15:4819-4824.
30. Ewing CM, Ru N, Morton RA, et al. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of a-catenin and restoration of E-cadherin function. Cancer Res. 1995;55:4813-4817.
31. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995;55:5195-5199.
32. Isaacs W, Bova S, Morton RA, et al. Molecular genetics and chromosomal alterations in prostate cancer. Cancer. 1995;75:2004-2012.
33. Otto T, Birchmeier W, Schmidt U, et al. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res. 1994;54:3120-3123.
34. Ross JS, del Rosario AD, Figge HL, et al. E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum Pathol. 1995;26:940-944.
35. Bringuier PP, Umbas R, Schaafsma HE, et al. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 1993;53:3241-3245.
36. Oyama T, Kanai Y, Ochiai A, et al. A truncated β-catenin disrupts the interaction between E-cadherin and a-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res. 1994;54:6282-6287.
37. Ross JS, Cheung C, Sheehan C, et al. E-cadherin cell adhesion molecule expression as a diagnostic adjunct in urothelial cytology. Diagn Cytopathol. 1996;14:310-315.
38. O'Donnell M, Fleming S. Disruption of cell adhesion in renal epithelium without cadherin loss. J Pathol. 1995;175:45-50.
39. Terpe HJ, Tajrobehkar K, Gunthert U, Altmannsberger M. Expression of cell adhesion molecules alpha-2, alpha-5 and alpha-6 integrin, E-cadherin, N-CAM and CD-44 in renal cell carcinomas: an immunohistochemical study. Virchows Arch A Pathol Anat Histopathol. 1993;422:219-224.
40. Günthert U, Stauder R, Mayer B, et al. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv. 1995;24:19-42.
41. Günthert U. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol. 1993;184:47-63.
42. Haynes BF, Telen MJ, Hale LP, Denning SM. CD44: a molecule involved in leukocyte adherence and T-cell activation. Immunol Today. 1989;10:423-128.
43. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med. 1994;180:53-66.
44. Latham MC. CD44 and cancer screening. Lancet. 1993; 342:548-549.
45. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol. 1993;54:271-335.
46. Herrlich P, Zöller M, Pals ST, Ponta H. CD44 splice variants: metastases meet lymphocytes. Immunol Today. 1993;14: 395-399.
47. Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol. 1993;122:257-264.
48. Ponta H, Sleeman J, Dall P, et al. CD44 isoforms in metastatic cancer. Invasion Metastasis. 1995;14:82-86.
49. Ruiz P, Schwärzler C, Günthert U. CD44 isoforms during differentiation and development. Bioessays. 1995;17:17-24.
50. Tarin D, Matsumura Y. Deranged CD44 gene activity in malignancy. J Pathol. 1993;171:249-250.
51. Thomas L, Byers HR, Vink J, Stamenkovic I. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol. 1992;118:971-977.
52. Underhill C. CD44: The hyaluronan receptor. J Cell Sci. 1992; 103:293-298.
53. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13-24.
54. Haynes BF, Hale LP, Patton KL, Martin ME, McCullum RM. Measurement of an adhesion molecule as an indicator of inflammatory disease activity: up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum. 1991;34:1434-1443.
55. Lokeshwar VB, Bourguignon LYW. The lymphoma transmembrane glycoprotein gp85 (CD44) is a novel guanine nucleotide-binding protein which regulates gp85 (CD44)-ankyrin interaction. J Biol Chem. 1992;267:22073-22078.
56. Hofmann M, Rudy W, Gunthert U, et al. A link between res and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res. 1993; 53:1516-1521.
57. Blumenfeld W, Ye JQ, Dahiya R, Griffiss JM, Narayan P. HLA expression by benign and malignant prostatic epithelium: augmentation by interferon-gamma. J Urol. 1993;150: 1289-1292.
58. Griebling TL, Cohen MB. The role of CD44 isoforms on cellular adhesion of human prostate cancer cell lines. Surg Forum. 1995;46:782-784.
59. Liu AY. Expression of CD44 in prostate cancer cells. Cancer Lett. 1994;76:63-69.
60. Lokeshwar BL, Lokeshwar VB, Block NL. Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Res. 1995;1191-1198.
61. Pretlow TG, Nagabhushan M, Sy M, Guo Y, Pretlow TP. Putative preneoplastic foci in the human prostate. J Cell Biochem. 1994;56:224-231.
62. Stevens JW, Palechek PL, Griebling TL, et al. Expression of CD44 isoforms in human prostate tumor cell lines. Prostate. 1996;28:153-161.
63. Matsumura Y, Sugiyama M, Matsumura S, et al. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol. 1995;177:11-20.
64. Southgate J, Trejdosiewicz LK, Smith B, Selby PJ. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder carcinoma cell lines. Int J Cancer. 1995;62:449-456.
65. Sugiyama M, Woodman A, Sugino T, et al. Non-invasive detection of bladder cancer by identification of abnormal CD44 proteins in exfoliated cancer cells in urine. J Clin Pathol. 1995; 48:M142-M147.
66. Steinbach F, Alexander J, Tanabe K, et al. Expression of cell adhesion molecules in an established and characterized new human renal cell cancer line, CCF-RC7. Urol Res. 1995;22:175-183.
67. Hathorn RW, Tso CL, Kaboo R, et al. In vitro modulation of the invasive and metastatic potential of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer. Cancer. 1994;74:1904-1911.
68. Dedhar S. Integrin mediated signal transduction in oncogenesis: an overview. Cancer Metastasis Rev. 1995;14:165-172.
69. Dedhar S, Jewell K, Rojiani M, Gray V. The receptor for the basement membrane glycoprotein entactin is the integrin α3/β1. J Biol Chem. 1992;267:18908-18914.
70. Bonkhoff H, Stein U, Remberger K. Differential expression of α6 and α2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum Pathol. 1993;24:243-249.
71. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KSD, Cress AE. Characterization of integrin subunits, cellular adhesion and tumorigenicity of four human prostate cell lines. J Cancer Res Clin Oncol. 1993;119:637-044.
72. Knox JD, Cress AE, Clark V, et al. Differential expression of extracellular matrix molecules and the α6-integrins in the normal and neoplastic prostate. Am J Pathol. 1994;145: 167-174.
73. Nagle RB, Knox JD, Wolf C, Bowden GT, Cress AE. Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl. 1994;19:232-237.
74. Rabinovitz I, Nagle RB, Cress AE. Integrin α6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis. 1995;13:481-191.
75. Jewell K, Kapron-Bras C, Jeevaratnam P, Dedhar S. Stimulation of tyrosine phosphorylation of distinct proteins in response to antibody-mediated ligation and clustering of alpha 3 and alpha 6 integrins. J Cell Sci. 1995;108:1165-1174.
76. Cress AE, Rabinovitz I, Zhu W, Nagle RB. The a6β1 and a6β4 integrins in human prostate cancer progression. Cancer Metastasis Rev. 1995;14:218-228.
77. Kostenuik PJ, Sanchez-Sweatman O, Orr FW, Singh G. Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the a2β1 integrin. Clin Exp Metastasis. 1996;14:19-26.
78. Liebert M, Washington R, Stein J, Wedemeyer G, Grossman HB. Expression of the VLA β1 integrin family in bladder cancer. Am J Pathol. 1994;144:1016-1022.
79. Liebert M, Washington R, Wedemeyer G, Carey TE, Grossman HB. Loss of co-localization of a6β4 integrin and collagen VII in bladder cancer. Am J Pathol. 1994;144:787-795.
80. Droz D, Patey N, Paraf F, Chretien Y, Gogusev J. Composition of extracellular matrix and distribution of cell adhesion molecules in renal cell tumors. Lab Invest. 1994;71:710-718.
81. Korhonen M, Laitinen L, Ylanne J, et al. Integrin distributions in renal cell carcinomas of various grades of malignancy. Am J Pathol. 1992;141:1161-1171.
82. Timmer A, Oosterhuis JW, Koops HS, et al. The tumor microenvironment: possible role of integrins and the extracellular matrix in tumor biological behavior of intratubular germ cell neoplasia and testicular seminomas. Am J Pathol. 1994;44:1035-1044.
83. Jackson AM, Alexandroff AB, McIntyre M, et al. Induction of ICAM-1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol. 1994;47:309-312.
84. Jackson AM, Alexandrov AB, Gribben SC, Esuvarnathan K, James K. Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int J Cancer. 1993;55:921-925.
85. Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD. Expression of adhesion molecules by bladder cancer cells: modulation by interferon-gamma and tumour necrosis factor-alpha. J Urol. 1992;148:1583-1586.
86. Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD. Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1. Immunology. 1992;76:286-291.
87. Tomita Y, Watanabe H, Kobayashi H, et al. Expression of intercellular adhesion molecule-1 on transitional cell cancer: possible significance in immunity against tumor cells. Am J Pathol. 1993;143:191-198.
88. Campbell SC, Tanabe K, Alexander JP, et al. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects. J Urol. 1994;151:1385-1390.
89. Alexandroff AB, Jackson AM, Esuvaranathan K, Prescott S, James K. Autocrine regulation of ICAM-1 expression on bladder cancer cell lines: evidence for the role of IL-1 alpha. Immunol Lett. 1994;40:117-124.
90. Hansen AB, Andersen CB. Comparison of the effects of tumour necrosis factor alpha stimulation and phorbol ester treatment on the immunocytochemical staining of intercellular adhesion molecule 1 in human renal carcinoma cell cultures. Virchows Arch B Cell Pathol. 1993;73:107-113.
91. Hansen AB, Bouchelouche PN, Andersen CB. Effects of pertussis and cholera toxin on the interferon-gamma stimulated immunocytochemical staining of ICAM-1 and inositol phosphate formation in a human renal carcinoma cell line. Virchows Arch B Cell Pathol. 1993;64:345-350.
92. Hansen AB, Bouchelouche PN, Giese BN, Andersen CB. Role of protein kinase C during interferon-gamma- and phorbol ester-stimulated immunocytochemical expression of ICAM-1 in human renal carcinoma cells. APMIS. 1993;101:437-448.
93. Hansen AB, Bouchelouche PN, Lillevangi ST, Andersen C. Interferon-gamma increases cellular calcium ion concentration and inositol 1,4,5-triphosphate formation in human renal carcinoma cells: relation to ICAM-1 antigen expression Br J Cancer. 1994;69:291-298.
94. Hansen AB, Lillevang ST, Andersen CB. Stimulation of intercellular adhesion molecule-1 (ICAM-1) antigen expression and shedding by interferon-γ and phorbol ester in human renal carcinoma cell cultures: relation to peripheral blood mononuclear cell adhesion. Urol Res. 1994;22:85-91.
95. Heicappell R, Podlinksi J, Buszello H, Ackerman R. Cell surface expression and serum levels of intercellular adhesion molecule-1 in renal cell carcinoma. Urol Res. 1994;22:9-15.
96. Minervini R, Panichi V, Viagno L, et al. Cellular expression of lymphocyte function-associated antigen-1 and intercellular adhesion molecule-1 in normal kidney structures and in renal cancer. Eur Urol. 1994;26:103-106.
97. Santarosa M, Favaro D, Quaia M, et al. Expression and release of intercellular adhesion molecule-1 in renal cancer patients. Int J Cancer. 1995;62:271-275.
98. Tomita Y, Imai T, Katagiri A, et al. Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle. Cancer Lett. 1993;75:27-34.
99. Yanase M, Tsukamoto R, Kunamoto Y, Kato K, Hashimoto Y. Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment. Cancer Immunol Immunother. 1994;39:22-16.
100. Kreft B, Bohnet S, Carstensen O, Hacker J, Marre R. Differential expression of interleukin-6, intracellular adhesion molecule 1, and major histocompatibility complex class II molecules in renal carcinoma cells stimulated with S fimbriae of uropathogenic Escherichia coli. Infect Immun. 1993;61:3060-3063.
101. Tomita Y, Watanabe H, Kobayashi H. Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer lines to lymphokine-activated killer cells. Cancer Immunol Immunother. 1992;35:381-387.
102. Obiri NI, Tandon N, Puir RK. Up-regulation of intercellular adhesion molecule 1 (ICAM-1) on human renal cell carcinoma cells by interleukin-4. Int J Cancer. 1995;61:635-642.
103. Tomita Y, Kimura M, Tanikawa T, et al. Immunohistochemical detection of intercellular adhesion molecule-1 (ICAM-1) and major histocompatibility complex class I antigens in seminoma. J Urol. 1993;149:659-663.
104. Hsieh JT, Luo W, Song W, et al. Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res. 1995;55:190-197.
105. Johnson RC, Zhu D, Augustin-Voss HG, Pauli BU. Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung-metastatic rat breast and prostate carcinoma cells. J Cell Biol. 1993;121:1423-1432.
106. Kleinerman DI, Zhang WW, Lin SH, et al. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res. 1995;55:2831-2836.
107. Kleinerman DI, Troncoso P, Lin SH, et al. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res. 1995;55:1215-1220.